Company Eli Lilly and Company Deutsche Boerse AG

Equities

LLY

US5324571083

Pharmaceuticals

Real-time Estimate Tradegate 01:27:09 17/05/2024 pm IST 5-day change 1st Jan Change
711.4 EUR -0.39% Intraday chart for Eli Lilly and Company -0.14% +35.10%

Business Summary

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:

- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;

- oncology (19.5%);

- immunology diseases (11.1%);

- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;

- other (3.3%).

Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Number of employees: 43,000

Sales per Business

USD in Million2022Weight2023Weight Delta
Human Pharmaceutical Products
100.0 %
28,541 100.0 % 34,124 100.0 % +19.56%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
63.9 %
18,190 63.7 % 21,791 63.9 % +19.80%
Europe
18.1 %
4,299 15.1 % 6,175 18.1 % +43.62%
Other Foreign Countries
8.6 %
2,852 10.0 % 2,946 8.6 % +3.30%
Japan
4.9 %
1,747 6.1 % 1,673 4.9 % -4.28%
China
4.5 %
1,453 5.1 % 1,540 4.5 % +5.98%

Managers

Managers TitleAgeSince
Chief Executive Officer 56 01/96/01
Director of Finance/CFO 51 01/01/01
President - -
Chief Tech/Sci/R&D Officer - 17/21/17
Chief Tech/Sci/R&D Officer - 16/23/16
Compliance Officer - 01/97/01
Chief Tech/Sci/R&D Officer 50 01/18/01
Corporate Officer/Principal - 01/05/01
Corporate Officer/Principal 49 -
Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 63 25/21/25
Director/Board Member 68 01/09/01
Director/Board Member 63 01/05/01
Director/Board Member 62 01/16/01
Director/Board Member 66 04/12/04
Chief Executive Officer 56 01/96/01
Director/Board Member 54 01/16/01
Director/Board Member 52 12/11/12
Director/Board Member 69 01/13/01
Director/Board Member 62 01/18/01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 950,770,386 948,828,863 ( 99.80 %) 365,000 ( 0.0384 %) 99.80 %

Shareholders

NameEquities%Valuation
Lilly Endowment, Inc.
10.40 %
98,898,810 10.40 % 77 250 M €
Vanguard Fiduciary Trust Co.
7.651 %
72,745,011 7.651 % 56 821 M €
The Vanguard Group, Inc.
7.531 %
71,604,696 7.531 % 55 930 M €
PNC Investments LLC
5.410 %
51,438,196 5.410 % 40 178 M €
BlackRock Advisors LLC
5.286 %
50,259,761 5.286 % 39 258 M €
34,258,566 3.603 % 26 759 M €
Fidelity Management & Research Co. LLC
3.583 %
34,063,734 3.583 % 26 607 M €
Capital Research & Management Co. (World Investors)
2.581 %
24,536,055 2.581 % 19 165 M €
PRIMECAP Management Co.
2.235 %
21,254,190 2.235 % 16 602 M €
T. Rowe Price International Ltd.
2.168 %
20,613,061 2.168 % 16 101 M €
NameEquities%Valuation
Caixa DTVM SA
0.001476 %
421,310 0.001476 % 11 M €
Western Asset Management Company DTVM Ltda.
0.000707 %
201,841 0.000707 % 5 M €
Bram Bradesco Asset Management S/A DTVM
0.000172 %
49,010 0.000172 % 1 M €
Safra Asset Management Ltda.
0.000157 %
44,900 0.000157 % 1 M €
Warren Brasil Gestão e Administração e Recursos Ltda.
0.000041 %
11,739 0.000041 % 306 866 €
XP Allocation Asset Management Ltda.
0.000014 %
3,883 0.000014 % 101 504 €
BTG Pactual WM Gestão de Recursos Ltda.
0.000009 %
2,450 0.000009 % 64 045 €

Holdings

NameEquities%Valuation
8,084,411 6.83% 50,293,848 $
13,371,562 16.55% 26,208,262 $
4,000,000 9.40% 20,920,000 $
21,776,804 7.60% 11,332,213 $
3,615,328 3.64% 8,279,101 $
125,405 1.81% 1,218,937 $

Company contact information

Eli Lilly & Co.

Lilly Corporate Center

46285, Indianapolis

+317 276 2000

http://www.lilly.com
address Eli Lilly and Company(LLY)

Group companies

NameCategory and Sector
Pharmaceuticals: Major
Pharmaceuticals: Major
Medical Distributors
Kinsale Financial Services
Miscellaneous Commercial Services
Pharmaceuticals: Major
Eli Lilly (Suisse) SA
Financial Conglomerates
Eli Lilly Vostok SA

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
771.1 USD
Average target price
850.4 USD
Spread / Average Target
+10.28%
Consensus
1st Jan change Capi.
+30.75% 59TCr
-1.60% 37TCr
+20.07% 33TCr
+6.04% 29TCr
+14.60% 24TCr
+10.00% 21TCr
-3.15% 21TCr
+9.27% 17TCr
+0.45% 16TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. LLY Stock
  5. Company Eli Lilly and Company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW